首页> 外文期刊>Human gene therapy methods. >Generation and Characterization of Adeno-Associated Virus Producer Cell Lines for Research and Preclinical Vector Production
【24h】

Generation and Characterization of Adeno-Associated Virus Producer Cell Lines for Research and Preclinical Vector Production

机译:腺相关病毒生产细胞系的产生和表征,用于研究和临床前载体的生产

获取原文
获取原文并翻译 | 示例
       

摘要

Adeno-associated virus (AAV) producer cell lines represent an effective method for large-scale production of AAV vectors. We set out to evaluate and characterize the use of an abbreviated protocol to generate "masterwells'' (MWs; a nonclonal cell population) as a platform for research and preclinical vector production. In this system, a single plasmid containing three components, the vector sequence, the AAV rep, and cap genes, and a selectable marker gene is stably transfected into HeLaS3 cells. Producer cell lines generating an AAV2 vector expressing a secreted form of human placental alkaline phosphatase (SEAP) have been created. Several MWs showed vector yields in the 5 x 10(4) to 2 x 10(5) DNase-resistant particles/cell range, and the productivity was stable over >60 population doublings. Integrated plasmid copy number in three high-producing MWs ranged from approximately 12 to 50; copies were arranged in a head-to-tail configuration. Upon infection with adenovirus, rep/cap copy number was amplified approximately 100-fold and high yield appeared to be dependent on the extent of amplification. Rep/cap gene expression and vector packaging both reached a peak at 48 hr postinfection. AAV2-SEAP vector was produced in 1-liter shaker culture and purified for assessment of vector quality and potency. The data showed that the majority of the capsids from the MWs contained vector DNA (>= 70%) and that purified vector was free of replication-competent AAV. In vitro and in vivo analyses demonstrated that potency of the producer cell-derived vector was comparable to vector generated via the standard transfection method.
机译:腺伴随病毒(AAV)生产细胞系代表了大规模生产AAV载体的有效方法。我们着手评估和表征使用缩写协议生成“ masterwells”(MW;非克隆细胞群)作为研究和临床前载体生产的平台。在该系统中,单个质粒包含三个成分,即载体序列,AAV rep和cap基因,以及一个选择标记基因被稳定地转染到HeLaS3细胞中,产生了产生表达人胎盘碱性磷酸酶(SEAP)形式的AAV2载体的生产细胞系,数个兆瓦显示了载体产量在5 x 10(4)到2 x 10(5)耐DNase的颗粒/细胞范围内,并且在> 60的种群倍增中,生产率保持稳定;三个高产MW中整合的质粒拷贝数在大约12至50之间腺病毒感染后,rep / cap的拷贝数被扩增了大约100倍,高产量似乎取决于扩增的程度。基因表达和载体包装均在感染后48小时达到峰值。 AAV2-SEAP载体是在1升摇床培养物中生产的,并经过纯化以评估载体的质量和效能。数据显示,来自MW的大部分衣壳含有载体DNA(> = 70%),并且纯化的载体不含能复制的AAV。体外和体内分析表明,生产者细胞来源的载体的效力与通过标准转染方法产生的载体相当。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号